Oral and inhaled @entity288 and XXXX : a case-control study.

@entity1 @entity1887 @entity228 @entity288
BACKGROUND: @entity1887 , a well recognised complication of treatment with oral @entity288 , has been described in association with inhaled @entity228 use in over 60 case reports. The risk of @entity1887 in @entity1 prescribed an oral or inhaled @entity228 in the general population is not known. A study was undertaken to quantify the association between @entity1887 and oral and inhaled @entity228 exposure. METHODS: A case-control study was performed using computerised general practice data from The Health Improvement Network. RESULTS: From a cohort of 2.4 million @entity1 , 154 cases of @entity1887 and 870 controls were identified. There was a dose related increased risk of @entity1887 in @entity1 prescribed an oral @entity228 with an odds ratio of 2.0 (95% CI 1.6 to 2.5) per course of treatment per year. @entity1887 was associated with a prescription for an inhaled @entity228 during the 90 day period before the diagnosis with an odds ratio of 3.4 (95% CI 1.9 to 5.9) and this effect was dose related (p for trend <0.001). After adjusting for oral @entity228 exposure, this odds ratio was reduced to 1.6 (95% CI 0.8 to 3.2) although the dose relation remained (p for trend 0.036). CONCLUSION: @entity1 prescribed an oral or inhaled @entity228 are at a dose related increased risk of @entity1887 although the absolute risk is small. This analysis suggests that the increased risk in @entity1 prescribed an inhaled @entity228 is largely due to oral @entity228 exposure, but inhaled @entity288 may have an effect when they are taken at higher doses.
